BusinessXeris Pharmaceuticals Achieves Phase 3 Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe HypoglycemiaBy Nasdaq OMXFeb 15, 2018, 10:00 PM UTC
BusinessXeris Pharmaceuticals, Inc. Appoints John P. Schmid to Board of DirectorsBy Nasdaq OMXSep 7, 2017, 8:30 PM UTC
BusinessXeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development ProgramBy Nasdaq OMXJun 16, 2017, 11:51 AM UTC
BusinessXeris Pharmaceuticals Announces Closing of $30 Million FinancingBy Nasdaq OMXMay 17, 2017, 11:00 PM UTC
BusinessXeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEOBy Nasdaq OMXJan 9, 2017, 12:00 PM UTC
BusinessXeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD MeetingBy Nasdaq OMXFeb 4, 2016, 3:22 PM UTC
BusinessXeris Pharmaceuticals Announces $41 Million Series C FinancingBy Nasdaq OMXJan 7, 2016, 3:25 PM UTC
